PSA density (PSAD): Role in patient evaluation and management

E. Seaman; M. Whang; C. A. Olsson; A. Katz; W. H. Cooner; M. C. Benson

doi:10.1016/s0094-0143(21)00918-6

PSA density (PSAD): Role in patient evaluation and management

E. Seaman
, M. Whang
, C. A. Olsson
, A. Katz
, W. H. Cooner
, M. C. Benson

Icahn School of Medicine at Mount Sinai

Research output: Contribution to journal › Article › peer-review

154 Scopus citations

Abstract

Prostate Specific Antigen (PSA) is the most accurate serum marker for cancer of the prostate. However, sensitivity and specificity are suboptimal, especially at the intermediate levels between 4.1 and 10.0 ng/ml(monoclonal). For intermediate PSA levels, prostate specific antigen density (PSAD) provides unique information regarding the need for biopsy and the likelihood of prostate cancer. This article summarizes the utility of PSAD in diagnosing and treating prostate cancer.

Original language	English
Pages (from-to)	653-663
Number of pages	11
Journal	Urologic Clinics of North America
Volume	20
Issue number	4
DOIs	https://doi.org/10.1016/s0094-0143(21)00918-6
State	Published - 1993

Access to Document

10.1016/s0094-0143(21)00918-6

Cite this

@article{f9996fa721d646be96cc4e4e95c850bb,

title = "PSA density (PSAD): Role in patient evaluation and management",

abstract = "Prostate Specific Antigen (PSA) is the most accurate serum marker for cancer of the prostate. However, sensitivity and specificity are suboptimal, especially at the intermediate levels between 4.1 and 10.0 ng/ml(monoclonal). For intermediate PSA levels, prostate specific antigen density (PSAD) provides unique information regarding the need for biopsy and the likelihood of prostate cancer. This article summarizes the utility of PSAD in diagnosing and treating prostate cancer.",

author = "E. Seaman and M. Whang and Olsson, \{C. A.\} and A. Katz and Cooner, \{W. H.\} and Benson, \{M. C.\}",

year = "1993",

doi = "10.1016/s0094-0143(21)00918-6",

language = "English",

volume = "20",

pages = "653--663",

journal = "Urologic Clinics of North America",

issn = "0094-0143",

publisher = "W.B. Saunders",

number = "4",

}

TY - JOUR

T1 - PSA density (PSAD)

T2 - Role in patient evaluation and management

AU - Seaman, E.

AU - Whang, M.

AU - Olsson, C. A.

AU - Katz, A.

AU - Cooner, W. H.

AU - Benson, M. C.

PY - 1993

Y1 - 1993

N2 - Prostate Specific Antigen (PSA) is the most accurate serum marker for cancer of the prostate. However, sensitivity and specificity are suboptimal, especially at the intermediate levels between 4.1 and 10.0 ng/ml(monoclonal). For intermediate PSA levels, prostate specific antigen density (PSAD) provides unique information regarding the need for biopsy and the likelihood of prostate cancer. This article summarizes the utility of PSAD in diagnosing and treating prostate cancer.

AB - Prostate Specific Antigen (PSA) is the most accurate serum marker for cancer of the prostate. However, sensitivity and specificity are suboptimal, especially at the intermediate levels between 4.1 and 10.0 ng/ml(monoclonal). For intermediate PSA levels, prostate specific antigen density (PSAD) provides unique information regarding the need for biopsy and the likelihood of prostate cancer. This article summarizes the utility of PSAD in diagnosing and treating prostate cancer.

UR - https://www.scopus.com/pages/publications/0027851294

U2 - 10.1016/s0094-0143(21)00918-6

DO - 10.1016/s0094-0143(21)00918-6

M3 - Article

C2 - 7505973

AN - SCOPUS:0027851294

SN - 0094-0143

VL - 20

SP - 653

EP - 663

JO - Urologic Clinics of North America

JF - Urologic Clinics of North America

IS - 4

ER -

PSA density (PSAD): Role in patient evaluation and management

Abstract

Access to Document

Fingerprint

Cite this